The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.
Ahmad SM, Martinenaite E, Holmström M, Jørgensen MA, Met Ö, Nastasi C, Klausen U, Donia M, Pedersen LM, Munksgaard L, Ødum N, Woetmann A, Svane IM, Andersen MH.
Ahmad SM, et al.
Oncoimmunology. 2017 Nov 1;7(2):e1390641. doi: 10.1080/2162402X.2017.1390641. eCollection 2018.
Oncoimmunology. 2017.
PMID: 29308318
Free PMC article.